ARCI announces Integrity Compliance Panel
« Return to News
For 2017, the standards are linked to four ARCI Model Rules that are often referred to as the National Uniform Medication Program. These include implementation of the ARCI/RMTC Controlled Therapeutic Schedule; use of an RMTC accredited testing laboratory; adoption of the Multi-Medication Rule Violation point system; and the independent administration of race day furosemide for those trainers/owners opting to use it.
ARCI president Ed Martin indicated that some individual regulators and industry entities have expressed a desire to have a formal certification program to help guide them in assessing whether races imported to their track or jurisdiction operate under key integrity regulatory standards.
Racetracks, ADW's and off track betting companies choose which tracks they will offer their customers. Usually these offerings require the consent of the appropriate horsemen's organization and approval of the regulatory entity.
Martin was adamant that the ARCI will not be involved in recommending or deciding which simulcast signals should be approved or not.
"That is up to the tracks, ADWs, OTBs, the local horseman's group, and the appropriate regulator, to make such decisions individually. All the ARCI will do is provide information for others to assess what weight to give it in making decisions affecting their customers or constituents," he said.
The concept of a compliance certification program emerged from the Compliance Committee created by past ARCI chair Mark Lamberth of Arkansas. It was included in the 2016 Stakeholder Input Project, where it received considerable support--57 percent--from those participating.
Some in the Thoroughbred industry have an interest in limiting the import of simulcast signals in some markets to those races operating under minimum integrity standards. This concept has been embodied in the federal legislative proposals that have been put forward, but not passed, since 2005. (ARCI)